Ensifentrine, a Novel PDE3 and PDE4 Inhibitor for the Treatment of COPD: Randomized, Double-Blind, Placebo-controlled, Multicenter, Phase III Trials (The ENHANCE Trials)
Related Posts
Zhang D, Tsai K, Santana C, Javaherian K, Lee M, Bergsneider M, Kim W, Wang MB, Vinters HV, Yan W, Heaney AP. Genetic profiling of[...]
Songo J, Whitehead HS, Phiri K, Kalande P, Lungu E, Phiri S, van Oosterhout J, Moses A, Hoffman RM, Moucheraud C. Uptake of the COVID-19[...]
Cho DJ, Bokhoor PI, Dermenchyan A, Brownell N, Delavin NL, Furlong S, Hoo J, Tibbe T, Chen LY, Vangala S, Waterman BA, Han M, Fonarow[...]